Induction of antitumor immunity utilizing autologous tumor proteins is an attractive approach to cancer therapy. However, better methods and stimulants to present these autologous proteins back to the immune system are needed. Here we identify streptavidin as a novel carrier protein and stimulant, and test the efficacy of both syngeneic (rat) and autologous vaccines (dogs) utilising streptavidin in combination with reduced soluble tumor proteins.
Rats receiving two vaccinations of syngeneic tumor vaccine demonstrated a significant (P<0.05) survival advantage compared with controls (adjuvant only). Notably, vaccination also led to remission rates of between 30 to 60% in the aggressive 9L glioma model.
Antibodies to streptavidin were detected in the serum of vaccinated rats however antibody levels did not correlate with the response. The cytokine TNFĴ was upregulated in vaccinetreated rats while ICAM1 was down regulated. Post-engraftment, vaccinated rats maintained 
INTRODUCTION
Cancer immunotherapy continues to gain recognition as an oncology treatment as new and improved cancer vaccines and other immune stimulants are produced. Utilizing a patient's own tumor proteins to produce a vaccine is an attractive concept and a number of autologous vaccines are undergoing pre-clinical evaluation (1) . Other immune therapies such as dendritic cell therapy have moved into the clinic but whilst they increase survival time in patients they do not initiate immunological rejection or remission of a tumor (2, 3) . Induction of immunological rejection and remission remains the holy grail of cancer therapy. As more information on the complexities of immune suppression and stimulation and how to manipulate these emerges, better immune therapies will follow.
Cancer vaccines aimed at promoting an immune response to combat cancer vary greatly in design from whole tumor cell, cell and tumor lysate, tumor antigen, dendritic cell-mediated, DNA-and bacterial-derived vaccines (4, 5) . Most of these approaches utilise the patient's own material either directly or for extraction or stimulation in vitro (6) . These autologous vaccine types match the patients MHC molecules as well as tumor-associated antigens. While this is an advantage, tumor cells or proteins alone generally have poor immunogenicity, probably because the antigens are readily tolerized and they differ little from self. Various immune-stimulants are used to overcome the tolerization effect (6, 7) ; the most well-known being Bacille Calmette-Guerin (BCG), which has been used with irradiated autologous tumor cells in several trials (6) . stage disease (8, 9) . Therefore, work to produce autologous vaccines, which can demonstrate efficacy in all stages of disease needs to continue.
In this study we identify streptavidin as a novel immunostimulant and utilize this characteristic for the development of both syngeneic and autologous vaccines. Syngeneic vaccines are assessed in the highly aggressive GS-9L rat glioma model (10) and autologous vaccines in a clinical setting for dogs presenting with advanced cancers.
This work is a novel approach to cancer vaccine development harnessing the immunogenic properties of bacterial proteins together with the modification of a patient's own tumor proteins.
MATERIALS AND METHODS

Cell line
The rat glioma GS-9L (9L) cell line derived from a N-nitrosomethylurea-induced glioma (ECACC Cat No: 94110705) was cultured in BME media (Life Technologies Australia Pty Ltd, Mulgrave, Victoria, Australia) supplemented with 10% fetal bovine serum (Life Technologies) and grown in standard conditions (37°C humidified incubator with 5% CO 2 ).
The 9L line was checked for mycoplasma and no additional authentication was performed. 
Rats
9L Glioma Model
Rats (> 13 weeks of age) were anaesthetized using fluorothane inhalation and injected with 1x10 6 9L glioma cells in 100 μl serum free BME media subdermally in the flank. Tumors were allowed to grow to approximately 1cm 3 and either perfused (described below) or excised and frozen immediately for processing into vaccines.
For orthotopic brain experiments, a flank tumor of approximately 1 cm 3 was harvested, cut into 1mm pieces and briefly stored at 4°C in serum free BME media. Rats were anaesthetized using fluorothane. A small hole was drilled in the left side of the rat skull into which a piece of the flank tumor was implanted, the hole sealed with bone wax (Ethicon, Somerville, New Jersey, USA), and the scalp closed. Buprenorphine (Temgesic, 0.4 mg/kg, Schering-Plough, Kenilworth, New Jersey, USA) was administered subcutaneously for pain relief. Following recovery, rats were monitored daily for signs of distress as described previously (11) .
Perfusions
Rats were anaesthetized, the thoracic cavity opened and 0.2 mL heparin (5000 U/mL, Celsus
Cincinnati, Ohio, USA) was injected into the left ventricle of the heart to prevent clotting. A needle was inserted via the left ventricle into the ascending aorta and the right atrium was cut.
The blood was cleared with a phosphate buffered saline (PBS) flush and then 30 mL of biotin-SS (0.5 mg/ml, Thermo Scientific, Scorsby, Victoria, Australia) was slowly perfused into the rat. This was followed by 20 mL 0.05 M TRIS buffer to flush out unreacted biotinylation reagent and block unbound amine groups. Tumors were removed and immediately frozen in liquid nitrogen. 
Initial vaccine trial
Acquired immunity experiments
Rats that survived the initial vaccine study and vaccine dosing studies (n=9) were considered in remission and assessed for acquired immunity. The surviving rats were split into 2 cohorts for rechallenge with cells or orthotopically with tumor.
Vaccine Components experiment
This experiment was designed to evaluate the individual components of the vaccine. In preliminary work we demonstrated that non-reduced tumor lysate had no effect on tumor growth (SI Figure 1 ) therefore this group was not retested. Five treatment groups were tested: group, 300 μg streptavidin (Genscript, Pistcataway, New Jersey, USA) was suspended in 1 ml SDS buffer and then processed.
Vaccine (50) was prepared by reducing 2 ml of tumor lysate for 1 hr in 20 mM TCEP; then 300 ug streptavidin (1 mg/ml) was added and incubated for 2 hrs at RT. Each 1 ml of reduced and streptavidin-labelled lysate was then processed and resuspended in 1.2 mL (0.6 mL PBS + 0.6 mL FIA). Vaccine (100) was prepared similarly except that 300 μg streptavidin was added to 1 ml reduced lysate. All groups received a second vaccination 3 weeks after the first.
Blood was collected from all rats 7 days after the second vaccination, at multiple time points after engraftment and at sacrifice.
Cytokine analysis
Cytokine profiling of rat serum was performed using the rat Cytokine Bioplex (Bio Rad, We developed an ELISA assay to measure the level of streptavidin-spcific antibodies in the serum. Maxisorp ELISA plates (NUNC, Roskilde, Denmark) were coated overnight at 4°C with streptavidin (100 μl/plate, 10 μg/ml in 0.1 M NaHC0 3 ) (Calbiochem, La Jolla, California, USA). Plates were then blocked in 3 % BSA in PBS for 1 hr at 37°C. Rat serum samples were diluted 1:1000 in 1 % BSA in PBS and 100 μl incubated on plate at 37°C for 1 hr. The plate was then washed 4 times with 0.05% Tween-20 in PBS and incubated with a goat anti-rat-HRP antibody (1:2000 in 1% BSA in PBS; Sigma-Aldrich) for 1 hr at 37°C.
Plates were washed again, TMB substrate (R and D Systems) added for 10 minutes and then the absorbance read at 450 nm.
Circulating immune cell profiling
Circulating white blood cell levels were measured by Fluorescence-activated cell sorting (FACS). A sample of blood was collected into a 0. 
Statistical Analysis
One way ANOVA survival curve statistical analyses and Tukey's multiple comparison tests were performed using Graph Pad Prism® 4. A P-value < 0.05 was considered significant. 
RESULTS
Initial vaccine shows efficacy with no adverse effects in rats with glioma
The initial vaccine trial comprised rats treated with 2 doses of 9L glioma vaccine or adjuvant to determine the safety and efficacy of the vaccine. The rats showed no adverse effects to the vaccination other than minor swelling at the vaccination site. Two of the 3 rats in the vaccinetreated group developed tumors, however 1 of these resolved over time and the tumor had disappeared by day 58 post-engraftment ( Figure 1A ). Two rats were considered "in remission" after surviving beyond 100 days and were kept for rechallenge in the acquired immunity experiments described below. By contrast, in control adjuvant-vaccinated rats the average tumor progression time until ethical endpoint was 35 days ( Figure 1B) . Overall there was a significant survival advantage in the vaccinated group compared to the adjuvant alone group (P < 0.05).
Immunity to glioma induced in rats with 2 vaccinations
Given the success of the initial vaccine trial, we next determined the optimal vaccine dosage regimen. One dose did not extend survival significantly over that of control rats (Figure 2A ).
However, significantly extended survival relative to that of the controls was observed for rats receiving 2 doses ( Figure 2B , P < 0.05) and 3 doses ( Figure 2C , P < 0.05).
Interferon-Ȗ levels were elevated significantly 21 days post tumor challenge in rats receiving 1 or 2 vaccinations compared to control (SI Figure 2 , P <0.05). IL-4 levels were decreased significantly at day 21 in rats receiving 1 or 2 vaccinations compared to control (SI Figure 2, P <0.05). There was no significant difference in vaccine efficacy of 2 doses whether administered i.p. (Figure 2B ) or s.c. (Figure 2D ) and all further vaccinations were given s.c. 
Nine rats from this trial showed no sign of tumor 150 days post-engraftment and were considered in remission. To ascertain whether acquired immunity had developed, 4 rats in remission (including the 2 surviving rats from the initial vaccine trial, Figure 1 ) were rechallenged with 9L glioma cells. A highly significant increase in response was observed with vaccinated rats surviving to 150 days with no sign of tumors ( Figure 2E , P < 0.01).
These results suggest that rats that responded to vaccination and could fight off a tumor challenge were immune to further 9L cell challenges possibly due to vaccine-induced immune memory.
To further assess the efficacy of the vaccine, 5 rats in remission and 6 untreated control rats had resected tumor sections engrafted orthotopically in the brain. No signs of tumor growth were observed in the vaccinated rats up to 150 days post-engraftment whereas all control mice died of disease within 25 days of orthotopic engraftment ( Figure 2F , P < 0.001). These results suggest that the vaccine can induce immunity across the blood brain barrier.
Streptavidin identified as the immunogenic agent
Having established the optimal dosing regimen for the vaccine and its ability to induce immunity, we were interested in determining the essential immunogenic components of the vaccine. Western blot analysis of vaccine proteins probed with serum from vaccine-treated rats detected 5 -6 bands between 50 and 75 kDa ( Figure 3A) . Proteomic profiling identified peptides with sequences matching streptavidin (52.8 kDa tetramer, data not shown) and this was confirmed by western blotting with anti-streptavidin ( Figure 3B ). This suggested that streptavidin was being inadvertently eluted from the streptavidin affinity column.
These results led us to hypothesise that streptavidin was eliciting the antibody response and stimulating the immune system. To test this, unperfused (non-biotinylated) tumor was applied to the streptavidin column. A complex banding pattern was observed ( Figure 3C ) suggesting that streptavidin itself was selecting the vaccine proteins. This likely occurs by binding to its RYD site via an RGD or similar sequence in the tumor proteins (12) . Increasing the SDS concentration of the buffer 10-fold (to 10 %) to disrupt the covalent bonds had little effect; the vaccine still yielded a complex vaccine profile even on non-biotinylated tumors (data not shown). These findings indicate that streptavidin has a high affinity for the bound tumor proteins.
Low dose streptavidin in combination with reduced vaccine proteins (Vaccine (50)) showed greatest efficacy in rat glioma
Having identified that streptavidin is the component common to all batches of vaccine we next tested the efficacy of the vaccine with or without key steps in the production process.
Rats that received the combination of reduced lysate linked with a 50 μg dose of streptavidin (Vaccine (50)) showed the greatest survival of all the groups with an average survival of 77 days compared with 38 days for control rats (P < 0.001, Figure 4A , Table 1 ). This combination also induced remission in 2 of 6 rats ( Figure 4B ) suggesting that both reduction of proteins and streptavidin dose are important factors in vaccine production. Doubling the dose of streptavidin (Vaccine (100)) did not increase survival ( Figure 4A , Table 1 ). Retesting Vaccine (50) versus controls and lower doses of streptavidin confirmed its survival advantage (SI Figure 3 , P < 0.05).
Circulating streptavidin antibodies developed following vaccination
Blood was collected 7 days following the second vaccination, at days 14, 28, 35 and 40 after engraftment, and at sacrifice; the serum were assayed for anti-streptavidin antibodies. Rats treated with streptavidin showed reactivity to streptavidin that remained stable until sacrifice 
Vaccine (50) and streptavidin alone induced responses in circulating cytokines
Circulating cytokine levels were assessed at day 21 post-engraftment, and/or at endpoint (Table 1, Figure 4 , SI Figure 4 ). The pro-inflammatory cytokine TNF-Ĵ demonstrated the most notable changes with levels at day 21 at least 3-fold higher in the Vaccine (50)-treated group than other groups ( Figure 4D ) . Levels remained significantly higher in rats from this group in remission (survival > 100 days, P < 0.05, Table 1 ) whereas the rats not in remission had signficantly lower endpoint levels (P < 0.05, Table 1 ).
IFN-Ȗ and the chemokine MIP-3A showed opposite profiles to TNF-Ĵ at endpoint with significantly lower levels in rats in remission and higher levels in the remaining Vaccine (50) group (P < 0.05, Table 1 ). Similarly, the pro-inflammatory interleukin 1 family cytokine IL-1α was significantly elevated in Vaccine (50)-treated rats not in remission. ICAM1, which can be induced by pro-inflammatory cytokines, was significantly lower in the Vaccine (50) group than in controls at day 21 post-engraftment ( Figure 4E , P < 0.05). No significant changes in cytokine levels were observed for rats treated with R-lysate or Vaccine (100). Figure 5 ); NK cells decreased significantly to below baseline for both groups (P < 0.05, Figure 5) ; and monocyte levels for the Vaccine (50) group decreased significantly below baseline and those of controls (P < 0.05, Figure 5 ). CD4 T cell levels increased significantly above the baseline following vaccination (Pretumor) in the Vaccine (50) rats (P < 0.05). Post-tumor, both CD4 and CD8 T cell levels in the Vaccine (50) group were maintained at normal baseline levels and significantly higher than those in the control group (P < 0.05, Figure 5 ). Neutrophil and lymphocyte levels remained stable with the exception of significantly lower lymphocyte levels in controls post-tumor (P < 0.05, Figure 5 ).
The vaccine extends survival of dogs with advanced cancer
Twenty five family pet dogs of a variety of breeds presenting with 9 different types of advanced cancer were treated with vaccines prepared from each dog's own tumor using the canine vaccine production method as part of a Phase I clinical trial. This method of vaccine production incorporated biotin to optimize linking of tumor proteins to streptavidin and had been previously validated in rat experiments (SI Figure 5) . Vaccine protein profiles (SI Figure 6 ) were similar to those for the rat glioma model (Figure 3) . The tumor types and survival data for this trial are shown in Figure 6 . As a reference for the natural history of the cancers in these animals, expected survival times were taken from either individual oncology reports or published literature (13) and were based on surgery alone or standard of care for the tumor type.
Of the 25 dogs included in this study, 11 had some burden of disease at vaccination ( Figure   6 ). This included inoperable tumor, relapse following chemotherapy, metastases or residual tumor remaining after surgery. Sixty three percent of these (7/11) survived longer than would otherwise be expected based on tumor grade, histology, and/or oncology report. 
around-time from tumor resection or biopsy also means minimal lag time to treatment; an important consideration in the clinical setting.
DISCUSSION
In this study we demonstrated that vaccines developed using our production method can stimulate the immune system to recognise and either slow tumor growth or induce tumor rejection. Prophylactic syngeneic vaccination of the 9L glioma rat model doubled survival in A key component of the vaccine is the protein streptavidin. We discovered that streptavidin is effective at selecting tumor proteins and stimulating the immune system. The binding of streptavidin to proteins is through its RYDS sequence which mimics the RGD cell adhesion domain of fibronectin (14) . There are over 60 integral membrane proteins that contain an RGD sequence and could potentially bind streptavidin (12, 15) . Many of these proteins such as integrins, VEGF-A, angiopoietin, osteopontin, and fibronectin have been shown to have a role in cancer development (16, 17) . -13-0157 immunogenicity (18) , utilizing soluble proteins sets our process apart as most other vaccines are derived from ethanol fixed or irradiated whole cells (19) (20) (21) . These soluble proteins are then reduced with TCEP, which permanently breaks disulphide bonds and provides a stable environment for proteins (22, 23) .
This combination (streptavidin plus reduced soluble proteins; Vaccine (50)) was crucial for tumor remission and rejection in the 9L glioma model. Other studies have successfully used different therapies to slow tumor growth (24, 25) , but to our knowledge this is the first report of inducing complete remission in rats using vaccines derived from solid tumors rather than cells in this aggressive model. Of note, while the 9L glioma model has been reported to be immunogenic (10), we observed 100% engraftment with no spontaneous remissions in keeping with other reports using this cell line (24, (26) (27) (28) .
Our results suggest that the vaccine modulates the immune response from a predominantly antibody response (to streptavidin) to a cell-mediated response (requiring the addition of the reduced tumor lysate). B cells were increased in both the vaccine and control groups following vaccination, demonstrating that the adjuvant FIA stimulates an increase in peripheral B cells as described previously (29) . However, by 21 days post engraftment, B-cell counts of vaccine-treated rats had returned to normal levels indicating again a switch to a cell-mediated response to the tumor. In vaccine-treated rats both CD4 and CD8 T-cell levels were maintained at normal baseline levels post tumor-engraftment whereas they decreased significantly in controls over the same time period. These observations suggest that the vaccine may aid and extend survival in part by maintaining production of CD4 and CD8 T cells during cancer progression. In support of the importance of maintaining normal lymphocyte levels, low lymphocyte levels in cancer patients are reported to be indicative of poorer prognosis and higher tumor grade (30) . Melanoma and colorectal cancer patients with a higher level of tumor-infiltrating lymphocyte (CTL) also have a better prognosis (31, 30) .
The key cytokine response observed was the up-regulation of TNF-Ĵ, which is known to have an antitumor effect and causes cancer cell apoptosis (32) . While streptavidin-only vaccinated rats showed increased survival they did not show the corresponding up-regulation of TNF-Į as in vaccine-treated rats. ICAM1, a cytokine implicated in tumor growth and metastasis (33) , was also down-regulated only in vaccine-treated rats.
Cytokine analysis also identified differences in the levels of IL-4 and INF-Ȗ between vaccinetreated and control rats. IL-4, which has been shown to modulate tumor progression and metastasis (34) , was decreased in vaccine-treated rats. Vaccine-treated rats also showed a significant increase in INF-Ȗ, which is a critical immune system component of the antitumor response (35) . INF-Ȗ together with lymphocytes not only provide protection against tumor development but also assist in sculpting the immunogenic phenotype of tumors for presentation as a "cancer immunoediting" process (36, 37) . Taken together the cytokine results suggest that the vaccine initiates a specific and effective immune antitumor response. Table 1 . Circulating cytokine response at endpoint relative to control vaccinated rats. The Vaccine (50) group was further divided into 2 groups, those surviving > 100 days, considered in remission; and the remainder. 
Group
